e-learning
resources
London 2016
Monday, 05.09.2016
IPF treatment I
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Annual rate of FVC decline in patients with IPF treated with pirfenidone: Pooled analysis from 3 pivotal studies
Paul Noble (Los Angeles, United States of America), Paul Noble, Carlo Albera, Willis Chou, Ulrich Costabel, Bann-mo Day, Ian Glaspole, Marilyn Glassberg, Lisa Lancaster, David Lederer, Steven Nathan, Carlos Pereira, John Stauffer, Jeffrey Swigris
Source:
International Congress 2016 – IPF treatment I
Session:
IPF treatment I
Session type:
Oral Presentation
Number:
1810
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Paul Noble (Los Angeles, United States of America), Paul Noble, Carlo Albera, Willis Chou, Ulrich Costabel, Bann-mo Day, Ian Glaspole, Marilyn Glassberg, Lisa Lancaster, David Lederer, Steven Nathan, Carlos Pereira, John Stauffer, Jeffrey Swigris. Annual rate of FVC decline in patients with IPF treated with pirfenidone: Pooled analysis from 3 pivotal studies. Eur Respir J 2016; 48: Suppl. 60, 1810
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials
Source: International Congress 2016 – IPF treatment I
Year: 2016
Effect of continued pirfenidone treatment following a ≥ 15% decline in 6-minute walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis from 3 pivotal studies
Source: International Congress 2016 – New and old therapies for chronic lung diseases
Year: 2016
Effect of baseline FVC on lung function decline with nintedanib in patients with IPF
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Analysis of patients with idiopathic pulmonary fibrosis (IPF) with percent predicted forced vital capacity (FVC)<50% treated with pirfenidone (PFD) in RECAP
Source: International Congress 2016 – IPF treatment I
Year: 2016
Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPD
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Effects of nintedanib in patients with progressive fibrosing ILDs and differing baseline FVC: further analyses of the INBUILD trial
Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin?
Year: 2020
Consistent effect of nintedanib on reducing FVC decline across interstitial lung diseases (ILDs)
Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment
Year: 2020
Short term Quantitative Lung Fibrosis (QLF) change predicts rapid rate of FVC decline in patients with IPF
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
Effect of low dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): results from a real life study
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
The magnitude of pirfenidone treatment effect in patients with idiopathic pulmonary fibrosis (IPF): A pooled analysis of outcomes in the CAPACITY (CAP) studies
Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis
Year: 2010
Effect of baseline FVC on decline in lung function with nintedanib: Results from the INPULSIS™ trials
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
Real World experiences: Pirfenidone is well tolerated and reduces decline in FVC and TLCO at 9 months in IPF
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Effect of pirfenidone on treatment-emergent (TE) all-cause mortality (ACM) in patients with idiopathic pulmonary fibrosis (IPF): Pooled data analysis from ASCEND and CAPACITY
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Year: 2015
The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing FVC at baseline: the SENSCIS trial
Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new?
Year: 2019
Lung function with aclidinium/formoterol fixed-dose combination: Pooled analysis of two phase III studies in COPD
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Association between weight loss and decline in FVC in patients with IPF
Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis
Year: 2019
Effect of baseline corticosteroid medication on reduction in FVC decline with nintedanib
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Lung function decline in COPD trials
Source: Eur Respir J 2009; 33: 708-709
Year: 2009
FVC decline over 1 year predicts mortality but not subsequent FVC decline in patients with IPF
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept